Andrew Gengos, President and CEO at ImmunoCellular Therapeutics, Ltd. (IMUC), bought 10,000 shares at $0.90 ($9K) on 2014-08-14, disclosed to the SEC on 2014-08-14.
Open-market purchase of $9k IMUC by President and CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| ATHA | SELL | 2024-09-05 | $725 | — | Filing → |
| ATHA | SELL | 2024-02-16 | $4K | — | Filing → |
| ATHA | SELL | 2024-01-08 | $4K | — | Filing → |